-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $570

Benzinga·07/07/2026 15:46:27
Listen to the news
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $543 to $570.